1-6 of 6
Sadie Roberts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Martin F Kaiser, Andrew Hall, Rachel Phillip, Amy Holroyd, Elsa Ferris, Sadie Roberts, Laura Clayton, Kristian Bowles, Mamta Garg, Anand Lokare, Ruth M de Tute, Mark Drayson, Christina Messiou, Roger G Owen, Richard S Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Sarah R Brown, Matthew W. Jenner
Journal: Blood
Blood (2024) 144 (Supplement 1): 3354.
https://doi.org/10.1182/blood-2024-201086
Published: 2024
Journal Articles

Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Rakesh Popat, Charlotte Pawlyn, Robert Cicero, Andrew Hall, Ceri Bygrave, Dean Smith, Simona Degli Esposti, Daniel Frank Larkin, Gordon Cook, Matthew W. Jenner, Martin F Kaiser, Lydia Sarah Hui Lee, Amrutha Sridhar, Marzia Rahman, Hanna Renshaw, Jennifer Ryan, Victoria Ware, Thea Chandler, Laura Clayton, Sadie Roberts, Sarah R Brown, Christopher Parrish
Journal: Blood
Blood (2024) 144 (Supplement 1): 1984.
https://doi.org/10.1182/blood-2024-204055
Published: 2024
Journal Articles

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Martin F. Kaiser, Rachel Phillip, Andrew Hall, Amy Holroyd, Laura Bevington, Ruth M de Tute, Laura Clayton, Sadie Roberts, Graham Jackson, Gordon Cook, Richard S Houlston, Mark Drayson, Roger Owen, Guy Pratt, Sarah R Brown, Matthew W. Jenner
Journal: Blood
Blood (2023) 142 (Supplement 1): 881.
https://doi.org/10.1182/blood-2023-177896
Published: 2023
Journal Articles

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Isabelle Smith, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T Drayson, Roger G Owen, Sarah R Brown, Matthew W Jenner
Journal: Blood
Blood (2022) 140 (Supplement 1): 1833–1835.
https://doi.org/10.1182/blood-2022-159540
Published: 2022
Journal Articles

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Katrina Walker, Nicola Newnham, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Gordon Cook, Guy Pratt, Roger G Owen, Mark T Drayson, Sarah R Brown, Matthew W Jenner
Journal: Blood
Blood (2021) 138 (Supplement 1): 465.
https://doi.org/10.1182/blood-2021-144990
Published: 2021
Journal Articles

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Matthew W Jenner, Andrew Hall, Sian E Faustini, Alexandra Pitchford, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G Owen, Sarah R Brown, Mark T Drayson, Martin F. Kaiser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2699.
https://doi.org/10.1182/blood-2021-149268
Published: 2021